Dr. Amaria on Genetically Modified TILs in Melanoma

Rodabe N. Amaria, MD
Published: Saturday, Oct 21, 2017



Rodabe N. Amaria, MD, department of Melanoma Oncology, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses using genetically modified tumor infiltrating lymphocytes (TILs) in patients with advanced melanoma.

A patient with metastatic melanoma will be subjected to a biopsy or resection of their tumor. The tumor is then taken to the laboratory to grow millions of T cells, explains Amaria. Once the patient needs treatment, the T cells can then be applied in addition to high-dose IL2 to promote the sustainability of the infused T cells.

<<< View more from the World Congress of Melanoma


Rodabe N. Amaria, MD, department of Melanoma Oncology, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses using genetically modified tumor infiltrating lymphocytes (TILs) in patients with advanced melanoma.

A patient with metastatic melanoma will be subjected to a biopsy or resection of their tumor. The tumor is then taken to the laboratory to grow millions of T cells, explains Amaria. Once the patient needs treatment, the T cells can then be applied in addition to high-dose IL2 to promote the sustainability of the infused T cells.

<<< View more from the World Congress of Melanoma

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x